



## Program Agenda

DAY 1 THURSDAY – JANUARY 10		
2:00-2:10pm	Welcome and introduction	
2:10-2:15	Introduction of keynote presenter	<b>Owen A. O'Connor</b>
2:15-3:00	Keynote address: Targeting the Cancer Epigenome: Implications in Understanding the PTCL	<b>Stephen B. Baylin, MD</b>
SESSION 1: Molecular Pathways: New Insights		
<b>Moderators:</b>	<b>Teresa Palomero; Steve Baylin</b>	
3:05-3:20	Microenvironment in ENKTL	<b>WS Kim</b>
3:25-3:40	The role of RHOA in PTCL	<b>Teresa Palomero</b>
3:45-4:00	Emerging role of jak/stat dysregulation in LGL leukemia pathogenesis	<b>Thomas Loughran</b>
4:05-4:20	Exploiting Pathway addiction- directions for new therapies	
4:25-4:40	<b>BREAK</b>	
SESSION 2: Novel Therapies		
<b>Moderators:</b>	<b>Pier Luigi Zinzani; Susan Bates</b>	
4:45-5:00	Are we ready to think about PTCL subtype specific therapy	<b>Pier Luigi Zinzani</b>
5:05-5:20	Moving beyond the single agent: Epigenetic based combinations	<b>Enrica Marchi</b>
5:25-5:40	Real world experiences with Chidamide	<b>Yuqin Song</b>
5:45-6:00	Novel drugs on the horizon: Mogamulizumab in ATL, PTCL, or CTCL	<b>Michinori Ogura</b>
6:05-6:20	PD-1 as a tumor suppressor gene in HTLV1	<b>Jurgen Ruland</b>
<b>6:25-9:00</b>	<b>Welcome Dinner</b>	
DAY 2 FRIDAY – JANUARY 11		
<b>7:00-8:00am</b>	<b>Verastem Oncology Breakfast Symposium</b>	
8:30-8:35	Day 2 opening remarks:	
SESSION 3: CTCL		
<b>Moderators:</b>	<b>Youn Kim, Ahmed Sawas</b>	
8:35-8:50	A comprehensive review of CTCL pathology	<b>Alejandro Gru</b>
8:55-9:10	Immunotherapy in CTCL	<b>M. Khodadoust</b>
9:15-9:30	Innate Immune Response in the treatment of CTCL	<b>Alain Rook</b>
9:35-9:50	Novel targets in CTCL: NK receptor inhibitors	<b>Armand Bensussan</b>
9:55-10:10	CTCL as an epigenetic disease	<b>Susan Bates</b>
10:15-10:35	<b>BREAK</b>	
SESSION 4: What would you do?		
<b>Moderators:</b>	<b>Andrei Shustov, Salvia Jain</b>	
10:35-10:55	Adoptive cellular approaches for PTCL therapy: A survey of the landscape	<b>Hema Dave</b>
10:55-11:10	Debate: A CHP is the new standard of care for all PTCL upfront	<b>Barbara Pro</b>
11:10-11:25	Debate: CHO(E)P remains the gold standard for most PTCL	<b>Lorenz Trumper</b>
11:25-11:40	<i>Audience participation/discussion</i>	
11:40-11:55	ASCT in 1 <sup>st</sup> remission should be considered in every patient	<b>Emmanuel Bachy</b>
11:55-12:10	ASCT in 1 <sup>st</sup> remission should not be considered in every patient	<b>Soon Thye Lim</b>
12:10-12:25	<i>Audience participation/discussion</i>	
<b>1:00-2:00 pm</b>	<b>Spectrum Symposium</b>	

11TH ANNUAL

**T-CELL****LYMPHOMA  
FORUM**

JANUARY 10-12, 2019

HILTON LA JOLLA TORREY PINES

LA JOLLA, CA, USA

TCELLFORUM.COM

**SESSION 5: A deep dive: A focus on select subtypes**

<b>Moderators:</b>	<b>Steve Rosen, Francine Foss</b>	
2:30-4:00	Distinguishing the many types of ALCL (ALK +/- sALCL; cALCL & breast ALCL)	<b>Elaine Jaffe</b>
2:50-3:05	New developments in cutaneous lymphomas	<b>Julia Scarisbrick</b>
3:10-3:25	EATL	<b>Govind Bhagat</b>
3:30-3:45	Transformed MF	<b>Steve Rosen</b>
3:50-4:05	ANKL	<b>Fumihiko Ishida</b>
4:10-4:30	MEITL	Soo Young Tan
4:35-4:45	<b>Break</b>	

**Announcement of the 2019 TCLLF Research Grant Winner**

4:45-4:55	<b>TCLLF Foundation Award</b>	<b>Toni Ann Lupinaci</b>
4:55-5:15	Update on 2017 research grant: Targeted Inhibition of CD47-SIRP $\alpha$ Requires Fc-Fc $\gamma$ R Interactions to Maximize Phagocytosis of T-cell Lymphomas	<b>Salvia Jain</b> (1 <sup>st</sup> winner of grant)

**SESSION 6: Poster presentations (10-minute presentations; no Q&A)**

<b>Moderators:</b>	<b>Francine M. Foss, Won Seog Kim, Owen A. O'Connor</b>	
5:15-5:25	1.	
5:27-5:37	2.	
5:39-5:49	3.	
5:51-6:01	4.	
6:03-6:13	5.	
<b>6:00-8:00</b>	<b>Poster Walk Reception</b>	

**DAY 3 SATURDAY – JANUARY 12**

<b>7:00-8:00am</b>	<b>Kyowa Kirin Breakfast Symposium</b>	
8:10-8:15am	Day 3 opening remarks:	

**SESSION 7: Registries and beyond**

<b>Moderators:</b>	<b>Won Seog Kim,</b>	
8:15-8:30	COMPLETE	<b>Francine Foss</b>
8:35-8:50	T-Cell Project	<b>Massimo Federico</b>
8:55-9:10	Korean registry and ICT	<b>SJ Kim</b>
9:15-9:30	Czech Republic	<b>Marek Trnety</b>
9:35-9:50	<b>BREAK</b>	

**SESSION 8: Industry Innovations**

<b>Moderators:</b>	<b>Francine M. Foss, Won Seog Kim, Owen A. O'Connor</b>	
10:05-10:20	Affimed: CD30	<b>Leila Alland</b>
10:25-10:40	Miragen: microRNA	<b>Paul Rubin</b>
10:45-11:00	Trillium Therapeutics	<b>Yaping Shou</b>
11:05-11:20	Kymera Therapeutics	<b>Jared Gollob</b>
11:25-11:40	Tempus: Using big data approaches to better understand PTCL	<b>Casey Frankenberger</b>
<b>11:40-12:00</b>	<b>BREAK</b>	



<b>SESSION 9: Wrap-up Highlights</b>		
<b>Moderators: Francine M. Foss, Won Seog Kim, Owen A. O'Connor</b>		
12:00-12:10	Summary perspective on subtypes of TCL	<b>Yok Lam Kwong</b>
12:10-12:20	Summary perspective on CTCL	<b>Madeleine Duvic</b>
12:30-12:40	Summary perspective on PTCL	<b>Claire Dearden</b>
12:40-12:50	Status of International Collaborations	<b>Owen O'Connor</b>
12:50-12:55	Closing remarks	<b>Francine Foss</b>
1:00	Adjourn—Box lunch	